Combining Single Strand Oligodeoxynucleotides and CRISPR/Cas9 to Correct Gene Mutations in b Thalassemia induced Pluripotent Stem Cells*
b Thalassemia (b Thal) is one of the most common genetic diseases in the world. The generation of patient specific b Thal induced pluripotent stem cells (iPSCs) correction of the disease causing mutations in those cells, and then differentiation into hematopoietic stem cells offers a new therapeutic strategy for this disease. Here, we designed a CRISPR/Cas9 to specifically target the Homo sapiens hemoglobin b (HBB) gene CD41/42( CTTT) mutation. We demonstrated that the combination of single strand oligodeoxynucleotides with CRISPR/Cas9 was capable of correcting the HBB gene CD41/42 mutation in b Thal iPSCs. After applying a correction specific PCR assay to purify the corrected clones followed by sequencing to confirm mutation correction, we verified that the purified clones retained full pluripotency and exhibited normal karyotyping. Additionally, whole exome sequencing showed that the mutation load to the exomes was minimal after CRISPR/Cas9 targeting. Furthermore, the corrected iPSCs were selected for erythroblast differentiation and restored the expression of HBB protein compared with the parental iPSCs. This method provides an efficient and safe strategy to correct the HBB gene mutation in b Thal iPSCs.
The Journal of Biological Chemistry